This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Peijia Medical Future Growth

Future criteria checks 2/6

Peijia Medical is forecast to grow earnings and revenue by 56.2% and 28.9% per annum respectively. EPS is expected to grow by 55.8% per annum. Return on equity is forecast to be -3.6% in 3 years.

Key information

56.2%

Earnings growth rate

55.8%

EPS growth rate

Medical Equipment earnings growth	40.3%
Revenue growth rate	28.9%
Future return on equity	-3.6%
Analyst coverage	Low
Last updated	28 Aug 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

SHSC:9996 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1,046	-46	-28	N/A	4
12/31/2025	835	-103	-131	N/A	4
12/31/2024	634	-194	-169	N/A	4
6/30/2024	517	-252	N/A	N/A	N/A
3/31/2024	479	-322	N/A	N/A	N/A
12/31/2023	441	-393	-900	-583	N/A
9/30/2023	399	-460	-921	-609	N/A
6/30/2023	357	-528	-942	-635	N/A
3/31/2023	304	-468	-760	-506	N/A
12/31/2022	251	-408	-579	-376	N/A
9/30/2022	227	-449	-684	-441	N/A
6/30/2022	204	-491	-790	-506	N/A
3/31/2022	170	-533	-710	-471	N/A
12/31/2021	137	-574	-629	-436	N/A
9/30/2021	106	-515	-446	-327	N/A
6/30/2021	76	-455	-262	-217	N/A
3/31/2021	57	-1,262	-235	-199	N/A
12/31/2020	39	-2,069	-207	-181	N/A
9/30/2020	33	-2,128	-203	-180	N/A
6/30/2020	28	-2,187	-200	-179	N/A
3/31/2020	23	-1,360	-158	-141	N/A
12/31/2019	19	-532	-116	-103	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 9996 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 9996 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 9996 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 9996's revenue (28.9% per year) is forecast to grow faster than the Hong Kong market (7.4% per year).

High Growth Revenue: 9996's revenue (28.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 9996 is forecast to be unprofitable in 3 years.

This company listing is no longer active

Peijia Medical Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Forecast to breakeven in 2025

Forecast to breakeven in 2024

Recent updates

Peijia Medical Limited, Annual General Meeting, Sep 30, 2024

First half 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in 1H 2023)

Peijia Medical Limited to Report First Half, 2024 Results on Aug 23, 2024

Full year 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.61 loss in FY 2022)

Less than half of directors are independent

Peijia Medical Limited to Report Fiscal Year 2023 Results on Jun 15, 2024

Full year 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.61 loss in FY 2022)

Peijia Medical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Forecast to breakeven in 2025

Peijia Medical Announces Successful Completion of Patient Enrollment for Pivotal TaurusTrio Transcatheter Aortic Regurgitation Clinical Trial

First half 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.14 loss in 1H 2022)

Less than half of directors are independent

First half 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.27 loss in 1H 2021)

Peijia Medical Limited to Report First Half, 2022 Results on Aug 19, 2022

Forecast to breakeven in 2024

Peijia Medical Limited Announces Executive Changes

Peijia Medical Limited Receives NMPA Approval for Registration Application of Fluxcap Balloon Guide Catheter

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC for the Registration Application of Tethys AS Aspiration Catheter

Peijia Medical Limited, Annual General Meeting, Jun 10, 2022

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.86 loss per share (vs CN¥4.43 loss in FY 2020)

Peijia Medical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Peijia Medical Limited Receives the Approval from the National Medical Products Administration for Syphonet® Stent Retriever

Peijia Medical Limited Announces First Patient Implant in Research Clinical Trial of Peijia's Highlife Trans-Septal Mitral Valve Replacement System in China

Peijia Medical Announces First Patient Implant in the Clinical Trial of Its Third-Generation Transcatheter Aortic Valve System TaurusNXT

Peijia Medical Limited Announces First Patient Implant in Clinical Trial of TaurusNXT

First half 2021 earnings released: CN¥0.27 loss per share (vs CN¥8.68 loss in 1H 2020)

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC of the Registration Application for TaurusElite

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.33 loss in FY 2019)

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.26 loss in FY 2019)

Peijia Medical Limited to Report Fiscal Year 2020 Results on Mar 29, 2021

Peijia Medical Limited Announces Patient Enrollment for the Clinical Trial Ofshenyi Stent Retriever

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies